Company intelligence / Profile preview

TATUM Bioscience

Sherbrooke, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

TATUM Bioscience is developing a proprietary synthetic biology platform to create multimodal nanofilaments—synthetic advanced biologics—that stimulate comprehensive antitumor immune responses. Their approach aims to combine the benefits of combination immunotherapy into a single agent, potentially offering safer and more effective cancer treatments. The company remains in preclinical development with no reported clinical trial outcomes yet.

Therapeutic areas: Oncology
Modalities: Nanofilament-based therapySynthetic advanced biologics (synABs)Biologic (general category)
Industry: Biotech

Partnerships

adMare BioInnovations Tx AcceleratorSCbioDrive Accelerator Program

Beyond the preview

Go deeper on TATUM Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TATUM Bioscience.

Explore the full profile